Foghorn Therapeutics Presents New Data On Selective SMARCA2 Inhibitor FHD-909 And Selective CBP And Selective EP300 Degrader Programs
Benzinga Newsdesk 1 year ago
BiotechNewsEventsGeneral
FHD-909 (LY4050784) advancing in Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population- Preclinical synergistic anti-tumor activity of FHD-909 in
FHD-909 (LY4050784) advancing in Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population
- Preclinical synergistic anti-tumor activity of FHD-909 in combination with pembrolizumab and KRAS inhibitors supports clinical exploration
- Selective CBP degrader combination approaches show promise in preclinical ER+ breast cancer models
- Further preclinical characterization of the therapeutic potential of the Selective EP300 degrader program to treat advanced hematological malignancies